Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | PPARA | Q07869 | 2/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280519 | 0.88 | CETP (0.37) | RXRARXRBRXRGALDH1A1EPHX1 | |
| SCHEMBL349730 | 0.84 | CETP (0.40) | ALDH1A1POLBHTT | |
| SCHEMBL349226 | 0.83 | CYP3A4 (0.42) | ALDH1A1POLBHTT | |
| SCHEMBL1643581 | 0.76 | SLC6A4 (0.44) | RXRARXRBRXRGALDH1A1SYK | |
| SCHEMBL2275883 | 0.75 | MAPK1 (0.35) | RXRARXRBRXRGALDH1A1SYK | |
| SCHEMBL1645250 | 0.74 | SLC6A4 (0.44) | RXRARXRBRXRGALDH1A1 | |
| SCHEMBL13521855 | 0.73 | MAPK1 (0.38) | EGFRRXRARXRBRXRGSYK | |
| SCHEMBL350170 | 0.72 | LMNA (0.37) | ALDH1A1POLBHTT | |
| SCHEMBL13761009 | 0.72 | RXRA (0.34) | RXRARXRBRXRGALDH1A1SYK | |
| SCHEMBL1570668 | 0.72 | CETP (0.41) | ALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | EGFR 2591/4885CYP4Z1 2597/4885RXRA 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.